4//SEC Filing
Moxie Dwight 4
Accession 0001479290-23-000102
CIK 0001479290other
Filed
Sep 6, 8:00 PM ET
Accepted
Sep 7, 5:37 PM ET
Size
7.0 KB
Accession
0001479290-23-000102
Insider Transaction Report
Form 4
Moxie Dwight
CLO & GC
Transactions
- Sale
Common Stock
2023-09-05$17.81/sh−23,853$424,920→ 55,066 total - Sale
Common Stock
2023-09-06$17.06/sh−11,000$187,704→ 44,066 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated June 05, 2023 by Mr. Moxie.
- [F2]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.44 to $18.20. Mr. Moxie undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.80 to $17.52. Mr. Moxie undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001803375
Filing Metadata
- Form type
- 4
- Filed
- Sep 6, 8:00 PM ET
- Accepted
- Sep 7, 5:37 PM ET
- Size
- 7.0 KB